Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lutetium[177Lu] Oxodotreotide in Advanced SSTR+ Neuroendocrine Neoplasms
NCT06398444Phase 3Recruiting
- Sponsor
- Sinotau Pharmaceutical Group
- Start
- Jun 2024
- Primary completion
- Jun 2027
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of lutetium Lu 177 dotatate in Neuroendocrine neoplasm (NEN), sponsored by Sinotau Pharmaceutical Group. Started Jun 2024; status: recruiting.
02
Drugs
lutetium Lu 177 dotatate
03
Conditions
Neuroendocrine neoplasm (NEN)
Beyond the preview
Go deeper on NCT06398444.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06398444.